Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021)
Rani Therapeutics Holdings (RANI) posted quarterly Total Non-Current Liabilities of $2.6 million for Q4 2021, down 65.8% year-over-year from $7.7 million in Q4 2020, and down 49.71% quarter-over-quarter from $5.2 million in Q3 2021.
Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
Rani Therapeutics Holdings' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $2.6 million for Q4 2021.
- In Q4 2021, Total Non-Current Liabilities fell 65.8% year-over-year to $2.6 million; the TTM figure through Dec 2021 stood at $2.6 million (down 65.8% YoY), while the FY2021 annual figure was $2.6 million, down 65.8% from the prior year.
- Total Non-Current Liabilities for Q4 2021 stood at $2.6 million, down from $5.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.4 million in Q2 2021, with the low at $2.6 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 5.25 Mn |
| Jun 30, 2021 | 9.36 Mn |
| Dec 31, 2020 | 7.72 Mn |